Polyphosphate Procoagulant for Anticoagulant Reversal and Hemophilia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies lack effective reversal methods, leading to complications such as hemorrhage and the transmission of infectious diseases, with no available antidotes for many anticoagulant drugs, and treatments for hemophilia are expensive and often ineffective.
Innovation Solution
Administration of polyphosphate (polyP) to accelerate blood coagulation by activating the contact pathway, reducing the effects of anticoagulant therapy, and treating hemophilia by normalizing clot dynamics, which is as effective as factor replacement or rFVIIa in hemophilia plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If replacement of missing factors or administration of specific antidotes is used to normalize coagulation, then coagulation abnormality is corrected, but risk of transmission of infectious disease increases and cost increases
Solution Approach 1:
The patent uses polyphosphate, a simple, inexpensive chemical compound that can be easily administered and cleared from the body, replacing expensive and risky blood products. Polyphosphate acts as a universal procoagulant that normalizes clotting without requiring human-derived products, thereby eliminating infectious disease transmission risk while maintaining effective coagulation correction.
2Reliability
If rFVIIa is used as a universal procoagulant agent, then anticoagulant reversal is achieved, but thromboembolic adverse events occur and extreme expense is associated
Solution Approach 1:
The patent changes the fundamental mechanism of action from using activated factor VII (which directly activates multiple coagulation factors and carries thromboembolic risk) to using polyphosphate (which activates the contact pathway and accelerates thrombin generation through a different biochemical pathway). This parameter change in the procoagulant mechanism achieves anticoagulant reversal while avoiding thromboembolic adverse events associated with rFVIIa.
3Reliability
If rFVIIa is used to treat hemophilia, then bleeding is controlled, but extreme expense is associated
Solution Approach 1:
The patent replaces expensive recombinant factor VIIa with polyphosphate, a inexpensive chemical compound that can be mass-produced and administered cost-effectively. Polyphosphate provides universal procoagulant activity that works in hemophilia patients without requiring expensive blood products or recombinant proteins, thereby controlling bleeding while dramatically reducing treatment cost.
4Reliability
If heparin is used as an anticoagulant, then thrombosis is prevented, but no antidote is available for low molecular weight heparins
Solution Approach 1:
The patent introduces polyphosphate as an intermediary substance that can reverse the anticoagulant effects of heparin and low molecular weight heparins. Polyphosphate activates the contact pathway and accelerates thrombin generation, thereby countering the inhibitory effects of heparin on factor Xa and thrombin. This intermediary approach provides a reversal mechanism where none previously existed, enabling safe use of heparin therapies with the ability to reverse complications when needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PolyP effectively shortens clot time in plasma with anticoagulants and in hemophilia patients, providing a safer and more cost-effective alternative for reversing anticoagulation and treating bleeding episodes.
Implementation Method 1
Administration of polyphosphate (polyP) to accelerate blood coagulation by activating the contact pathway
Data Source
AI summary
A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.